Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers
Source: SeekingAlpha
2025-10-07 12:05:00 ET
What does the Pfizer-Trump deal cover?
The deal between the Trump Administration and Pfizer (PFE) provides clarity about the near-term future of the US patent-protected pharmaceutical sector after months of (tariff) uncertainty. If companies manufacture and invest in the US, they will be exempt from tariffs. This means that the margin risk from tariffs is largely muted, as branded pharma companies from the US, Europe, and Asia have already announced additional US investments in the next few years....
Read the full article on Seeking Alpha
For further details see:
Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers
iShares Biotechnology ETF
NASDAQ: IBB
IBB Trading
-0.92% G/L:
$165.11 Last:
850,028 Volume:
$167.72 Open:
